ZIMLAB137.20

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹734 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
ZIMLAB
FY26
ANUHPHR
FY26
VALIANTLAB
FY26
AHCL
FY26
Peer
Median
Valuation — at last close
P/E115.29×22.37×2.91×12.64× +812%
P/B2.48×2.61×0.37×1.49× +66%
EV/EBITDA27.72×14.03×2.82×8.42× +229%
Market Cap₹734 Cr₹919 Cr₹94.5 Cr₹507 Cr +45%
Growth
Revenue CAGR 3Y-2.06%
Net Income CAGR 3Y-37.95%
Revenue YoY (latest Q)31.25%3.93%146.22%75.08% -58%
Net Income YoY (latest Q)-114.25%37.63%1058.93%548.28% -121%
Profitability
EBITDA Margin8.02%8.00%2.69%27.63%8.00% +0%
Net Income Margin1.56%5.32%-1.38%16.92%5.32% -71%
Return on Common Equity1.97%11.65%-1.05%11.19%11.19% -82%
Return on Capital Employed2.87%14.21%0.10%17.26%14.21% -80%
Return on Assets1.08%7.36%-0.70%7.78%7.36% -85%
Credit & Quality
Total Debt/Equity0.42×0.00×0.14×0.17×0.14× +200%
Interest Coverage0.76×106.58×0.18×12.30×12.30× -94%
Scale — latest FY
Revenue / Total Income₹374 Cr₹772 Cr₹237 Cr₹172 Cr₹237 Cr +58%
Net Income₹5.8 Cr₹41 Cr−₹3.3 Cr₹29.1 Cr₹29.1 Cr -80%
Total Assets₹539 Cr₹557 Cr₹464 Cr₹374 Cr₹464 Cr +16%
EPS₹1.19₹4.1₹-0.51₹6.11₹4.1 -71%
Book Value per Share₹55.36₹35.14₹57.24₹47.94₹47.94 +15%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.